Synagis Related Published Studies
Well-designed clinical trials related to Synagis (Palivizumab)
Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. [2007.07]
Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis model. [2007.04]
Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. [2005.11]
Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. [2004.08]
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. [2003.10]
Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab). [2002.06]
[Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections] [2000.05]
Well-designed clinical trials possibly related to Synagis (Palivizumab)
Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions. [2000.01]
Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. [1998.12]
Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. [1998.02]
Other research related to Synagis (Palivizumab)
Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry. [2008.10]
Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. [2008.07]
EMLA cream and nitrous oxide to alleviate pain induced by palivizumab (Synagis) intramuscular injections in infants and young children. [2008.06]
Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. [2008.06]
Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. [2008.05]
Palivizumab Use in Subjects with Congenital Heart Disease : Results from the 2000-2004 Palivizumab Outcomes Registry. [2008.03]
The cost and safety of multidose use of palivizumab vials. [2008.03]
Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. [2008]
Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. [2007.12]
Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. [2007.10.15]
Palivizumab Use in Subjects with Congenital Heart Disease : Results from the 2000-2004 Palivizumab Outcomes Registry. [2007.10.10]
Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease. [2007.09]
[Indications and prescription modalities of palivizumab in neonates] [2007.09]
Respiratory syncytial virus: seasonal data for regions of Florida and implications for palivizumab. [2007.07]
Evaluation of compliance with palivizumab recommendations in a multicenter study of young children presenting to the emergency department with bronchiolitis. [2007.06]
[Respiratory syncytial immunoprophylaxis with palivizumab] [2007.05]
Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia. [2007.03]
Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. [2007]
Beyond randomized controlled trials: A "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. [2006.12]
The effect of an interventional program on adherence to the american academy of pediatrics guidelines for palivizumab prophylaxis. [2006.11]
Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. [2006.10]
[The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain] [2006.10]
Results of clinical surveillance during the Japanese first palivizumab season in 2002-2003. [2006.08]
Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. [2006.05]
A 4-year survey on palivizumab respiratory syncytial virus (RSV)-prophylaxis: how can compliance be improved? [2006.04]
Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease--who should receive it? [2006.04]
The potential impact of palivizumab on pediatric airway reconstruction. [2006.01]
Passive immunisation of preterm infants with palivizumab against RSV infection. [2006.01]
Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: a national survey. [2005.10]
Palivizumab in the prophylaxis of respiratory syncytial virus infection. [2005.10]
Safety and efficacy of palivizumab prophylaxis in children with congenital heart disease. [2005.08]
Palivizumab for preterm infants. Is it worth it? [2005.07]
Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. [2005.01]
Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. [2004.12.01]
Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit? [2004.12]
Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. [2004.12]
Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. [2004.12]
Economic analysis of palivizumab in infants with congenital heart disease. [2004.12]
Palivizumab use in very premature infants in the neonatal intensive care unit. [2004.11]
[Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society.] [2004.11]
Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden. [2004.11]
Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. [2004.09.01]
Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit. [2004.09]
Rate of palivizumab administration in accordance with current recommendations among hospitalized children. [2004.09]
Quantitative effects of palivizumab and donor-derived T cells on chronic respiratory syncytial virus infection, lung disease, and fusion glycoprotein amino acid sequences in a patient before and after bone marrow transplantation. [2004.07.15]
Deaths among children less than two years of age receiving palivizumab: an analysis of comorbidities. [2004.04]
Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. [2004.01.20]
Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002. [2004.01]
Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection. [2004]
Respiratory syncytial virus-related pneumonia after stem cell transplantation successfully treated with palivizumab and steroid therapy. [2004]
Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease? [2003.11]
Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. [2003.10]
[Potential impact and cost-efficacy of bronchiolitis prophylaxis with palivizumab in preterm infants with a gestational age of less than 33 weeks] [2003.10]
Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. [2003.09]
Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use. [2003.09]
Safety of palivizumab in preterm infants 29 to 32 weeks' gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection. [2003.07]
Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. [2003.06]
Palivizumab outcomes registry data from Spain: Infeccion Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group. [2003.02]
Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. [2003.02]
Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. [2003]
[Prevention of respiratory syncytial virus infection by SYNAGIS (palivizumab)] [2002.12]
Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants. [2002.12]
Palivizumab in the prevention of respiratory syncytial virus disease. [2002.10]
Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV. [2002.09]
Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis. [2002.09]
Cost-effectiveness of palivizumab in New Zealand. [2002.08]
Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. [2002.06]
Optimum dosage regimen of palivizumab? [2002.06]
Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model. [2002.01]
Home delivery of palivizumab: outcomes and compliance in regional preterm infants. [2002.01]
Factors predicting compliance with palivizumab in high-risk infants. [2001.09]
Developing a synagis clinic for respiratory syncytial virus prophylaxis. [2001.09]
Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. [2001.08.01]
The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit. [2001.07]
Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group. [2001.06]
Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants. [2001.03.24]
Palivizumab in infants with gestational age < or = 28 weeks and bronchopulmonary dysplasia. [2001]
Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. [2000.11]
Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. [2000.11]
Prevention of respiratory syncytial virus infection with palivizumab. [2000.08]
A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. [2000.03]
Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection. [2000.02.01]
[Use of palivizumab in the prevention of syncytial virus respiratory infection] [2000]
Palivizumab: an overview. [1999.12]
[Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)] [1999.11]
Synagis: an anti-RSV monoclonal antibody. [1999.09]
Palivizumab. [1999.08]
Palivizumab for respiratory syncytial virus prophylaxis. [1999.07]
Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. [1999.04]
Other possibly related research studies
Immunoglobulin treatment for respiratory syncytial virus infection. [2006.10.18]
Significant morbidity associated with RSV infection in immunosuppressed children following liver transplantation: Case report and discussion regarding need of routine prophylaxis. [2006.11]
|
